Statin drugs deny prostate cancer cells access to needed hormones, delaying disease progression
the ONA take:
Cholesterol-lowering statin drugs were shown to delay disease progression in men with prostate cancer when statins were also initiated with androgen deprivation therapy (ADT), according to a clinical trial from Dana-Farber Cancer Institute.
In the study, men who had been taking statins since the start of ADT went a median of 27.5 months before experiencing disease progression, compared with 17.4 months for men who were not taking statins.
Laboratory studies focusing on the SLCO2B1 protein found that the protein helps a variety of drugs and hormones enter cells, including both statin drugs and dehydroepiandrosterone sulfate (DHEAS), a precursor of testosterone, the hormone that spurs prostate cancer cell growth.
Using laboratory-grown prostate cancer cell lines, the researchers found that statin drugs monopolized available SLCO2B1 thereby depriving prostate cancer cells of the hormones they need to grow.
The trial involved 926 patients, and 70% of participants experienced disease progression during a 6-year period.
Although this mechanism by which statins may work in prostate cancer can improve patient outcomes, the researchers state that further study is needed to validate their findings.
Statins were shown to delay disease progression in men with prostate cancer when statins were also initiated with ADT.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|